MARKET

DRMA

DRMA

Dermata Therapeutics Inc
NASDAQ
2.260
+0.060
+2.73%
After Hours: 2.290 +0.03 +1.33% 17:07 01/06 EST
OPEN
2.265
PREV CLOSE
2.200
HIGH
2.298
LOW
2.130
VOLUME
103.88K
TURNOVER
--
52 WEEK HIGH
23.70
52 WEEK LOW
1.580
MARKET CAP
2.66M
P/E (TTM)
-0.0797
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DRMA last week (1229-0102)?
Weekly Report · 1d ago
Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 12/30/2025 17:31
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/30/2025 17:05
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus
Benzinga · 12/30/2025 10:21
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/30/2025 09:43
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
Benzinga · 12/30/2025 05:54
Dermata Therapeutics Raises Capital via December Private Placement
TipRanks · 12/29/2025 21:31
Dermata Therapeutics Announces $12.4 Million Private Placement With Warrants and Share Issuance
Reuters · 12/29/2025 21:06
More
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Webull offers Dermata Therapeutics Inc stock information, including NASDAQ: DRMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRMA stock methods without spending real money on the virtual paper trading platform.